Endocan: a novel predictor of endothelial dysfunction in obstructive sleep apnea syndrome
Background and Aims Obstructive sleep apnea syndrome (OSA) is an independent risk factor for endothelial dysfunction and cardiometabolic diseases. Plasma endocan levels are elevated in a large number of diseases, and is a novel surrogate endothelial cell dysfunction marker. We aimed to assess the ro...
Gespeichert in:
| Veröffentlicht in: | The clinical respiratory journal 2018-01, Vol.12 (1), p.84-90 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 90 |
|---|---|
| container_issue | 1 |
| container_start_page | 84 |
| container_title | The clinical respiratory journal |
| container_volume | 12 |
| creator | Kanbay, Asiye Ceylan, Erkan Köseoğlu, Handan İnönü Çalışkan, Mustafa Takir, Mumtaz Tulu, Selcan Telci Çaklılı, Ozge Köstek, Osman Erek, Aybala Afsar, Baris |
| description | Background and Aims
Obstructive sleep apnea syndrome (OSA) is an independent risk factor for endothelial dysfunction and cardiometabolic diseases. Plasma endocan levels are elevated in a large number of diseases, and is a novel surrogate endothelial cell dysfunction marker. We aimed to assess the role of serum endocan level as a potential mechanism of endothelial dysfunction in OSA patients.
Materials and Methods
This was a cohort study in which patients who had undergone a sleep study for diagnosis of OSA were recruited. Included patients were grouped according to apnea‐hypopnea index (AHI) as mild, moderate and severe OSA. Patients with AHI |
| doi_str_mv | 10.1111/crj.12487 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826676046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826676046</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-d5af9024331072336c049399b9c0a30f15e1e88a400e5e7c559647f809752aa63</originalsourceid><addsrcrecordid>eNp1kMtKBDEQRYMoPkYX_oAE3OhiNOl0Xu5k8IkgiIKuQiZdjT30JG3SPTJ_b3TUhWBtqoo6XG5dhPYpOaG5Tl2cndCiVHINbVPJi7HQ-nn9d1Z0C-2kNCOEK8n4JtoqJKWiUHIbvVz4Kjjrz7DFPiygxV2EqnF9iDjUGPK1f4W2sS2ulqkevOub4HHjcZimPg55XQBOLUCHbefB4rT0VQxz2EUbtW0T7H33EXq6vHicXI_v7q9uJud3Y8c4k-OK21qTomSMElkwJhwpNdN6qh2xjNSUAwWlbEkIcJCOcy1KWSui83PWCjZCRyvdLoa3AVJv5k1y0LbWQxiSoaoQQgpSfqKHf9BZGKLP7gzVSnBeltnHCB2vKBdDShFq08VmbuPSUGI-8zY5b_OVd2YPvhWH6RyqX_In4AycroD3poXl_0pm8nC7kvwACYyIgQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1986554443</pqid></control><display><type>article</type><title>Endocan: a novel predictor of endothelial dysfunction in obstructive sleep apnea syndrome</title><source>Wiley Online Library (Open Access Collection)</source><creator>Kanbay, Asiye ; Ceylan, Erkan ; Köseoğlu, Handan İnönü ; Çalışkan, Mustafa ; Takir, Mumtaz ; Tulu, Selcan ; Telci Çaklılı, Ozge ; Köstek, Osman ; Erek, Aybala ; Afsar, Baris</creator><creatorcontrib>Kanbay, Asiye ; Ceylan, Erkan ; Köseoğlu, Handan İnönü ; Çalışkan, Mustafa ; Takir, Mumtaz ; Tulu, Selcan ; Telci Çaklılı, Ozge ; Köstek, Osman ; Erek, Aybala ; Afsar, Baris</creatorcontrib><description>Background and Aims
Obstructive sleep apnea syndrome (OSA) is an independent risk factor for endothelial dysfunction and cardiometabolic diseases. Plasma endocan levels are elevated in a large number of diseases, and is a novel surrogate endothelial cell dysfunction marker. We aimed to assess the role of serum endocan level as a potential mechanism of endothelial dysfunction in OSA patients.
Materials and Methods
This was a cohort study in which patients who had undergone a sleep study for diagnosis of OSA were recruited. Included patients were grouped according to apnea‐hypopnea index (AHI) as mild, moderate and severe OSA. Patients with AHI < 5 served as control group. Endothelial function was evaluated with flow‐mediated dilatation (FMD). Plasma endocan level was measured for all patients.
Results
One hundred twenty eight OSA patients included (15 controls, 22 with mild, 22 with moderate and 69 with severe OSA). The mean age was 51.6 ± 11.9 years and 43.8% (56/128) of the study population was female. As expected, the prevalence of hypertension, diabetes and cardiovascular disease increased as the severity of OSA increased. Endocan levels were significantly higher and FMD measurements were lower in patients with OSA compared to healthy controls. There was a positive correlation between AHI and serum endocan levels (rho = 0.826, P < 0.0001) and there was a negative correlation between AHI and FMD (rho = −0.686, P < 0.0001) In addition, we observed a strong negative correlation between serum endocan level and FMD (rho = −0.613, P < 0.0001). In linear regression analysis AHI was independently related both with endocan (P < 0.0001) and FMD (P = 0.011).
Conclusion
Serum endocan level is strongly associated with the severity of OSA and endothelial dysfunction. Endocan might be a useful early novel marker for premature vascular endothelial system damage in OSA patients.</description><identifier>ISSN: 1752-6981</identifier><identifier>EISSN: 1752-699X</identifier><identifier>DOI: 10.1111/crj.12487</identifier><identifier>PMID: 27116287</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Biomarkers - blood ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - physiopathology ; Cross-Sectional Studies ; endocan ; endothelial dysfunction ; Endothelium, Vascular - physiopathology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Proteins - blood ; obstructive sleep apnea ; Polysomnography ; Prognosis ; Proteoglycans - blood ; Risk Factors ; Sleep apnea ; Sleep Apnea, Obstructive - blood ; Sleep Apnea, Obstructive - complications ; Sleep Apnea, Obstructive - physiopathology ; Vasodilation - physiology</subject><ispartof>The clinical respiratory journal, 2018-01, Vol.12 (1), p.84-90</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><rights>Copyright © 2018 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-d5af9024331072336c049399b9c0a30f15e1e88a400e5e7c559647f809752aa63</citedby><cites>FETCH-LOGICAL-c3537-d5af9024331072336c049399b9c0a30f15e1e88a400e5e7c559647f809752aa63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcrj.12487$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcrj.12487$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,11562,27924,27925,45574,45575,46052,46476</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcrj.12487$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27116287$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kanbay, Asiye</creatorcontrib><creatorcontrib>Ceylan, Erkan</creatorcontrib><creatorcontrib>Köseoğlu, Handan İnönü</creatorcontrib><creatorcontrib>Çalışkan, Mustafa</creatorcontrib><creatorcontrib>Takir, Mumtaz</creatorcontrib><creatorcontrib>Tulu, Selcan</creatorcontrib><creatorcontrib>Telci Çaklılı, Ozge</creatorcontrib><creatorcontrib>Köstek, Osman</creatorcontrib><creatorcontrib>Erek, Aybala</creatorcontrib><creatorcontrib>Afsar, Baris</creatorcontrib><title>Endocan: a novel predictor of endothelial dysfunction in obstructive sleep apnea syndrome</title><title>The clinical respiratory journal</title><addtitle>Clin Respir J</addtitle><description>Background and Aims
Obstructive sleep apnea syndrome (OSA) is an independent risk factor for endothelial dysfunction and cardiometabolic diseases. Plasma endocan levels are elevated in a large number of diseases, and is a novel surrogate endothelial cell dysfunction marker. We aimed to assess the role of serum endocan level as a potential mechanism of endothelial dysfunction in OSA patients.
Materials and Methods
This was a cohort study in which patients who had undergone a sleep study for diagnosis of OSA were recruited. Included patients were grouped according to apnea‐hypopnea index (AHI) as mild, moderate and severe OSA. Patients with AHI < 5 served as control group. Endothelial function was evaluated with flow‐mediated dilatation (FMD). Plasma endocan level was measured for all patients.
Results
One hundred twenty eight OSA patients included (15 controls, 22 with mild, 22 with moderate and 69 with severe OSA). The mean age was 51.6 ± 11.9 years and 43.8% (56/128) of the study population was female. As expected, the prevalence of hypertension, diabetes and cardiovascular disease increased as the severity of OSA increased. Endocan levels were significantly higher and FMD measurements were lower in patients with OSA compared to healthy controls. There was a positive correlation between AHI and serum endocan levels (rho = 0.826, P < 0.0001) and there was a negative correlation between AHI and FMD (rho = −0.686, P < 0.0001) In addition, we observed a strong negative correlation between serum endocan level and FMD (rho = −0.613, P < 0.0001). In linear regression analysis AHI was independently related both with endocan (P < 0.0001) and FMD (P = 0.011).
Conclusion
Serum endocan level is strongly associated with the severity of OSA and endothelial dysfunction. Endocan might be a useful early novel marker for premature vascular endothelial system damage in OSA patients.</description><subject>Biomarkers - blood</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cardiovascular Diseases - physiopathology</subject><subject>Cross-Sectional Studies</subject><subject>endocan</subject><subject>endothelial dysfunction</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Proteins - blood</subject><subject>obstructive sleep apnea</subject><subject>Polysomnography</subject><subject>Prognosis</subject><subject>Proteoglycans - blood</subject><subject>Risk Factors</subject><subject>Sleep apnea</subject><subject>Sleep Apnea, Obstructive - blood</subject><subject>Sleep Apnea, Obstructive - complications</subject><subject>Sleep Apnea, Obstructive - physiopathology</subject><subject>Vasodilation - physiology</subject><issn>1752-6981</issn><issn>1752-699X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtKBDEQRYMoPkYX_oAE3OhiNOl0Xu5k8IkgiIKuQiZdjT30JG3SPTJ_b3TUhWBtqoo6XG5dhPYpOaG5Tl2cndCiVHINbVPJi7HQ-nn9d1Z0C-2kNCOEK8n4JtoqJKWiUHIbvVz4Kjjrz7DFPiygxV2EqnF9iDjUGPK1f4W2sS2ulqkevOub4HHjcZimPg55XQBOLUCHbefB4rT0VQxz2EUbtW0T7H33EXq6vHicXI_v7q9uJud3Y8c4k-OK21qTomSMElkwJhwpNdN6qh2xjNSUAwWlbEkIcJCOcy1KWSui83PWCjZCRyvdLoa3AVJv5k1y0LbWQxiSoaoQQgpSfqKHf9BZGKLP7gzVSnBeltnHCB2vKBdDShFq08VmbuPSUGI-8zY5b_OVd2YPvhWH6RyqX_In4AycroD3poXl_0pm8nC7kvwACYyIgQ</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>Kanbay, Asiye</creator><creator>Ceylan, Erkan</creator><creator>Köseoğlu, Handan İnönü</creator><creator>Çalışkan, Mustafa</creator><creator>Takir, Mumtaz</creator><creator>Tulu, Selcan</creator><creator>Telci Çaklılı, Ozge</creator><creator>Köstek, Osman</creator><creator>Erek, Aybala</creator><creator>Afsar, Baris</creator><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201801</creationdate><title>Endocan: a novel predictor of endothelial dysfunction in obstructive sleep apnea syndrome</title><author>Kanbay, Asiye ; Ceylan, Erkan ; Köseoğlu, Handan İnönü ; Çalışkan, Mustafa ; Takir, Mumtaz ; Tulu, Selcan ; Telci Çaklılı, Ozge ; Köstek, Osman ; Erek, Aybala ; Afsar, Baris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-d5af9024331072336c049399b9c0a30f15e1e88a400e5e7c559647f809752aa63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biomarkers - blood</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cardiovascular Diseases - physiopathology</topic><topic>Cross-Sectional Studies</topic><topic>endocan</topic><topic>endothelial dysfunction</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Proteins - blood</topic><topic>obstructive sleep apnea</topic><topic>Polysomnography</topic><topic>Prognosis</topic><topic>Proteoglycans - blood</topic><topic>Risk Factors</topic><topic>Sleep apnea</topic><topic>Sleep Apnea, Obstructive - blood</topic><topic>Sleep Apnea, Obstructive - complications</topic><topic>Sleep Apnea, Obstructive - physiopathology</topic><topic>Vasodilation - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanbay, Asiye</creatorcontrib><creatorcontrib>Ceylan, Erkan</creatorcontrib><creatorcontrib>Köseoğlu, Handan İnönü</creatorcontrib><creatorcontrib>Çalışkan, Mustafa</creatorcontrib><creatorcontrib>Takir, Mumtaz</creatorcontrib><creatorcontrib>Tulu, Selcan</creatorcontrib><creatorcontrib>Telci Çaklılı, Ozge</creatorcontrib><creatorcontrib>Köstek, Osman</creatorcontrib><creatorcontrib>Erek, Aybala</creatorcontrib><creatorcontrib>Afsar, Baris</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The clinical respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Kanbay, Asiye</au><au>Ceylan, Erkan</au><au>Köseoğlu, Handan İnönü</au><au>Çalışkan, Mustafa</au><au>Takir, Mumtaz</au><au>Tulu, Selcan</au><au>Telci Çaklılı, Ozge</au><au>Köstek, Osman</au><au>Erek, Aybala</au><au>Afsar, Baris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endocan: a novel predictor of endothelial dysfunction in obstructive sleep apnea syndrome</atitle><jtitle>The clinical respiratory journal</jtitle><addtitle>Clin Respir J</addtitle><date>2018-01</date><risdate>2018</risdate><volume>12</volume><issue>1</issue><spage>84</spage><epage>90</epage><pages>84-90</pages><issn>1752-6981</issn><eissn>1752-699X</eissn><abstract>Background and Aims
Obstructive sleep apnea syndrome (OSA) is an independent risk factor for endothelial dysfunction and cardiometabolic diseases. Plasma endocan levels are elevated in a large number of diseases, and is a novel surrogate endothelial cell dysfunction marker. We aimed to assess the role of serum endocan level as a potential mechanism of endothelial dysfunction in OSA patients.
Materials and Methods
This was a cohort study in which patients who had undergone a sleep study for diagnosis of OSA were recruited. Included patients were grouped according to apnea‐hypopnea index (AHI) as mild, moderate and severe OSA. Patients with AHI < 5 served as control group. Endothelial function was evaluated with flow‐mediated dilatation (FMD). Plasma endocan level was measured for all patients.
Results
One hundred twenty eight OSA patients included (15 controls, 22 with mild, 22 with moderate and 69 with severe OSA). The mean age was 51.6 ± 11.9 years and 43.8% (56/128) of the study population was female. As expected, the prevalence of hypertension, diabetes and cardiovascular disease increased as the severity of OSA increased. Endocan levels were significantly higher and FMD measurements were lower in patients with OSA compared to healthy controls. There was a positive correlation between AHI and serum endocan levels (rho = 0.826, P < 0.0001) and there was a negative correlation between AHI and FMD (rho = −0.686, P < 0.0001) In addition, we observed a strong negative correlation between serum endocan level and FMD (rho = −0.613, P < 0.0001). In linear regression analysis AHI was independently related both with endocan (P < 0.0001) and FMD (P = 0.011).
Conclusion
Serum endocan level is strongly associated with the severity of OSA and endothelial dysfunction. Endocan might be a useful early novel marker for premature vascular endothelial system damage in OSA patients.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>27116287</pmid><doi>10.1111/crj.12487</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1752-6981 |
| ispartof | The clinical respiratory journal, 2018-01, Vol.12 (1), p.84-90 |
| issn | 1752-6981 1752-699X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826676046 |
| source | Wiley Online Library (Open Access Collection) |
| subjects | Biomarkers - blood Cardiovascular Diseases - blood Cardiovascular Diseases - etiology Cardiovascular Diseases - physiopathology Cross-Sectional Studies endocan endothelial dysfunction Endothelium, Vascular - physiopathology Female Follow-Up Studies Humans Male Middle Aged Neoplasm Proteins - blood obstructive sleep apnea Polysomnography Prognosis Proteoglycans - blood Risk Factors Sleep apnea Sleep Apnea, Obstructive - blood Sleep Apnea, Obstructive - complications Sleep Apnea, Obstructive - physiopathology Vasodilation - physiology |
| title | Endocan: a novel predictor of endothelial dysfunction in obstructive sleep apnea syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T10%3A48%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endocan:%20a%20novel%20predictor%20of%20endothelial%20dysfunction%20in%20obstructive%20sleep%20apnea%20syndrome&rft.jtitle=The%20clinical%20respiratory%20journal&rft.au=Kanbay,%20Asiye&rft.date=2018-01&rft.volume=12&rft.issue=1&rft.spage=84&rft.epage=90&rft.pages=84-90&rft.issn=1752-6981&rft.eissn=1752-699X&rft_id=info:doi/10.1111/crj.12487&rft_dat=%3Cproquest_24P%3E1826676046%3C/proquest_24P%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1986554443&rft_id=info:pmid/27116287&rfr_iscdi=true |